By continuing to use our service, you agree to our use of cookies. 38. Theratechnologies Inc. com uses cookies on this site. 25 to $1. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has decided to pause the enrollment of patients in its Phase 1 clinical trial of. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies' (TH) Senior Vice President and Chief Medical Officer Dr. Theratechnologies’ R&D staff is bearing the brunt of. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. On average, they expect the company's stock price to reach $36. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced dosing of the first participant in Part 3 of its Phase 1 clinical trial of. Stockhouse. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies’ Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV. By continuing to use our service, you agree to our use of cookies. About Theratechnologies Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. Find the latest Theratechnologies Inc. Theratechnologies Inc. TH 48% v4,15M c1. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] (TH) has posted net revenue estimates for fourth quarter and the full fiscal year ending Nov 30, 2020. TORONTO, Sept. We also use them to share usage. 2% per year. MONTREAL, April 03, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Montréal, Québec, Canada . 16%. - Cash, bonds and money market funds of US$22. 30, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. (THTX) stock. L. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 13, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. TH1902 combines Theratechnologies’ proprietary peptide to. It is the Company’s proprietary peptide linked to docetaxel – a commonly used cytotoxic agent used to treat many cancers. 22, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Early Warning Report Issued Pursuant to National Instrument 62-103 - Acquisition of Securities of Theratechnologies Inc. Senior Director, Investor Relations. Gary Littlejohn Stockhouse. By continuing to use our service, you agree to our use of cookies. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Apr 14, 2020, 8:30 a. Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. (TSX-V: TLT, Forum) has demonstrated proof-of-concept for its Canadian-made COVID-19 vaccine. 9% more than in 2021. Find more information. 10% most volatile stocks in CA Market. Cookies are used to offer you a better browsing experience and to analyze our traffic. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of the 2023 Industrial Research Sectoral Group (RSRI) Innovation Award from the CQDM (for. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Common Shares (THTX) Stock Price, Quote, News & History | Nasdaq Nasdaq Data Link's products page Investors may trade in the Pre-Market (4:00. GUD | Complete Knight Therapeutics Inc. (2021-01-19 | TSX:TH) Theratechnologies Announces Closing of US$46 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option. TH | October 13, 2022. com. Their average twelve-month price target is $36. (2022-09-12 | TSX:TH) Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Fri, 17 Apr 2015 15:08:33 GMT ~ Supreme Court of Canada rules in favour of Theratechnologies. Data presented at AMCP Nexus 2023. Montréal, Québec, Canada . We currently market prescription products for people with HIV in the United States. Stockhouse. 617-356-1009. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a. 10% least volatile stocks in CA Market. 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (2022-02-24 | TSX:TH) Theratechnologies Reports Financial Results for Fiscal 2021 and Provides Business Update. In collaboration with the University of Manitoba (UM), the company demonstrated that its photodynamic compound (PDC),. 01, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Biopharmaceutical company Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. 31K. 1M. 00%. A high-level overview of Theratechnologies Inc. 14, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. [email protected] Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update T. stock news by MarketWatch. TO) stock quote, history, news and other vital information to help you with your stock trading and investing. This work is well underway and will be considered by the SAC as part of their meeting, which is scheduled for the latter half of March when the analyses are expected to be ready. MONTREAL, Jan. Theratechnologies to Announce Financial Results for Its First Quarter 2022. C. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its. Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors Stockhouse. TORONTO, May 19, 2023 /CNW/ - This press release is being disseminated as required by. This news release constitutes a “designated news release” for the purposes of the. 8 and 1. Cookies are used to offer you a better browsing experience and to analyze our traffic. (THTX) NasdaqCM - NasdaqCM Real Time Price. MONTREAL, Dec. TH | October 13, 2022 - Q3 2022 Consolidated. 40%) (As of 11/17/2023 ET) Compare Today's Range $1. Cookies are used to offer you a better browsing experience and to analyze our traffic. Cookies are used to offer you a better browsing experience and to analyze our traffic. By continuing to use our service, you agree to our use of cookies. We also use them to share usage information with our partners. D. . Stockhouse. NEW YORK, Dec. The SORT1 receptor plays a significant role in protein internalization, sorting and trafficking. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650For the three- and six-month periods ended May 31, 2023, consolidated revenue was $17,549,000 and $37,457,000, compared to $19,268,000 and $37,825,000 for the same periods ended May 31, 2022. We also use them to share usage. " The 12-month stock price forecast is $18. European Headquarters. 23) earnings per share over the last year ( ($1. MONTREAL, Feb. 04) earnings per share (EPS) for the quarter. 81 million for the quarter. T. THERATECHNOLOGIES INC. By continuing to use our service, you agree to our use of cookies. The company reported ($0. For investor inquiries: Leah Gibson. It is the Company’s proprietary peptide linked to. , a biopharmaceutical company, engages in the discovery of therapeutic products for commercialization. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. com. “This is yet another major achievement for our oncology program. Cookies are used to offer you a better browsing experience and to analyze our traffic. Cookies are used to offer you a better browsing experience and to analyze our traffic. When this page refreshes you will be logged in with the new address. Follow. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. 03) EPS for the quarter, beating the consensus estimate of ($0. La Bourse de Toronto a clôturé en hausse mardi pour une troisième séance consécutive, tandis que les grands indices boursiers américains ont avancé eux aussi. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. This news release constitutes a “designated news release” for the purposes of the Company’s. (NASDAQ:NASDAQ:THTX) Q3 2022 Earnings Conference Call October 13, 2022 8:30 AM ETCompany ParticipantsElif McDonald - Head of Investor RelationsPaul Levesque -. is an employee of TaiMed Biologics USA, Inc. Proceeds to Be Used to Redeem All of the Outstanding 5. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. Theratechnologies’ CFO to Attend Cantor Global Healthcare Conference in New York City. Stockhouse. (2021-11-03 | TSX:TH) Theratechnologies to Present at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021. Non-Profit & Charitable Organizations · United States · <25 Employees. GlobeNewswire. (NASDAQ:NASDAQ:THTX) Q1 2021 Earnings Conference Call April 14, 2021 8:30 AM ETCompany ParticipantsDenis Boucher - Vice President,. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) ), a biopharmaceutical company focused on the development. S. Further. The price has fallen in 7 of the last 10 days and is down by -30. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. View real-time stock prices and stock quotes for a full financial overview. The company had revenue of $20. Conjugating the short peptide with various anti-cancer agents allows for. Whether TH1902 impacts the chemoresistance phenotype of human triple-negative breast CSC. TH | March 7, 2023. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . Remember, high Theratechnologies' alpha is almost always a sign of. 04, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies develops and commercializes innovative therapies. sBLA for F8 formulation of tesamorelin submitted to FDA. Cookies are used to offer you a better browsing experience and to analyze our traffic. (TSE:TH) posted its quarterly earnings data on Tuesday, September, 26th. /NOT FOR DISTRIBUTION TO UNITED STATES OF AMERICA WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OF AMERICA/. (Theratechnologies, or the Company (on a consolidated basis)) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on. Headquarters. By continuing to use our service, you agree to our use of cookies. Heures de négociation. Theratechnologies Announces Operational Update - read this article along with other careers information, tips and advice on BioSpace Theratechnologies Inc. Theratechnologies Inc. Theratechnologies Announces 1-for-4 Reverse Stock Split. European Headquarters. FDA for its IV push form of administration of Trogarzo. [at noodls] - Montreal, Canada - April 17, 2015 - Theratechnologies Inc. (TH. 5%. : 001-35203 Mr. com. Investor inquiries: Elif McDonald. Theratechnologies Inc. com 10/16/2023. The Company currently commercializes two products in the field of HIV. Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates. About Theratechnologies Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. Stockhouse. (2021-05-31 | TSX:TH) Theratechnologies Hires Vice President, Human Resources. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced today that it will report its financial results for the second quarter of fiscal 2021 ended May 31, 2021 on Wednesday. The Montreal-based biopharmaceutical company's consolidated net revenues for fourth quarter 2020 are expected to be between US$18. 4. Theratechnologies inc. Canadian Commercial-Stage Biopharmaceutical Company Theratechnologies Announces NASDAQ Listing. T. By continuing to use our service, you agree to our use of cookies. 36 morning pop. TH1902, a newly developed sortilin (SORT1)-targeted peptide-docetaxel conjugate is currently in phase-1 clinical trial. Cookies are used to offer you a better browsing experience and to analyze our traffic. Senior Director, Investor Relations. The abstracts are now available at aacr. Theratechnologies Provides Details About R&D Day Webcast. 66% compared to the previous year's 69. The Canadian company develops peptide sequences to treat endocrine and metabolic conditions such as growth hormone deficiencies. T. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of. During the last trading day the stock fluctuated 12. Senior Director, Investor Relations. org. By continuing to use our service, you agree to our use of cookies. is a pharmaceutical company, which engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). com uses cookies on this site. 4% annually. Theratechnologies inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Who is Theratechnologies. Amendment Withdraws the Condition to File HFS Report to the FDA to Access the US$20 Million Second Tranche. Stockhouse. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. We also use them to share usage information with our partners. Get the latest Theratechnologies Inc (THTX) real-time quote, historical performance, charts, and other financial information to help you make more informed. MONTREAL, Oct. Biopharmaceutical company Theratechnologies (TH) has closed its bought deal public offering after raising over C$58 million in proceeds. Shares of Theratechnologies are up 4. 12, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. “Theratechnologies’ commitment to investors at the beginning of 2023 has been to remain steadfast in delivering on key financial objectives, particularly to achieve positive adjusted EBITDA by the end of the current fiscal year,” said Philippe Dubuc, Senior Vice President and Chief Financial Officer at Theratechnologies. Stockhouse. com uses cookies on this site. Top 173 largest Canadian Companies in the Drug Manufacturers—Specialty & Generic industry by Market Cap. 3. The financial results presented in this press release are taken from the. FAQ – Utilisateurs de TMX Argent NOUVEAU. 30, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. FY2023 Revenue Guidance Range Confirmed Between $90 million and $95 million; Growth of the Commercial Portfolio in the Range of 13% and 19%. This enduring webinar with Drs Arsalan Shah, Sarah Rowan, Stacey Trooskin, and Juliana Wallace will provide critical updates on specific strategies to improve testing and linkage to care, retention in care, and an overview of guidelines for treatment of HIV and HCV. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. US Headquarters. Theratechnologies presented the pre-clinical and clinical data gathered thus far to the SAC, which made recommendations to modify the frequency of administration, selection of tumor types and. com uses cookies on this site. One reason for that is that this tier does not include penny stocks. a biopharmaceutical company focused on the development and commercialization of innovative therapies, today initiated enrollment of patients in the basket portion of the first-in-human study of TH1902, Theratechnologies’ investigational lead peptide drug conjugate (PDC) for the treatment of sortilin-expressing. See a list of the most recent Stock Forum posts on Stockhouse. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has established an at-the-market ("ATM") equity program allowing Theratechnologies to. UN) today announces steps to strengthen its financial position, including financing and disposition initiatives, and a reduction to its monthly distribution. GlobeNewswire. If you have HIV, it's important to know the difference. com. Theratechnologies' CFO to Attend Piper Jaffray 31st Annual Healthcare Conference in New York City. 26, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. We currently market. By continuing to use our service, you agree to our use of cookies. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. Cookies are used to offer you a better browsing experience and to analyze our. 1-514-336-7800. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 ir@theratech. 33. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ¨ Form 40-F xMain number: 514-336-7800. View real-time stock prices and stock quotes for a full financial overview. (“Theratechnologies” or the “Company”) (TSX: TH) today announced that it has applied to list its common shares on NASDAQ. 4% from the stock's current price. lgibson. - Issued and outstanding common shares to be consolidated on the basis of 1 post-consolidation share for each 4 pre-consolidation shares issued and outstanding, to regain compliance with NASDAQ listing requirements. 00. Stockhouse. m. 75%. Stockhouse. 2015 Peel St 11TH Fl, Montreal, Quebec, H3A 1T8, Canada. MONTREAL, June 22, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Headquartered in Montreal, Theratechnologies is a biotech company that develops innovative therapies for unmet medical needs in HIV, oncology, and NASH, a type of liver disease. Montreal-based biopharmaceutical company Theratechnologies Inc. 72%. This news release constitutes a “designated news release” for the purposes. ( THTX 3. 's motion for leave to commence. Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies inc. Overview Stock Screener Earnings Calendar Sectors Nasdaq | THTX U. - 2023 Q3 positive adjusted EBITDA to be. The webinar will also address system-level barriers and present real-world. Theratechnologies Announces 1-for-4 Reverse Stock Split. com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. TH1902 is currently Theratechnologies’ lead investigational PDC candidate for the treatment of cancer derived from its SORT1+ Technology™. The business had revenue of $27. Theratechnologies affirms fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the range of 13% and 20% as. Theratechnologies (TH) has announced preclinical findings for its peptide-drug conjugate TH1902 for the treatment of metastatic cancers. 1-514-336-7800. MONTREAL, April 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. . It is highly expressed in cancer cells compared to healthy tissue, which makes SORT1 an. Cookies are used to offer you a better browsing. It is the Company’s proprietary. Cookies are used to offer you a better browsing experience and to. 08). By continuing to use our service, you agree to our use of cookies. 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Early Warning Report Issued Pursuant to National Instrument 62-103 - Acquisition of Securities of Theratechnologies Inc. VANCOUVER, British Columbia, Nov. MONTREAL, Sept. stock price gained 1. The company develops treatments for lipodystrophy . m. 9 million, adjusted EBITDA of $2. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its third quarter of fiscal 2022 ended August 31, on Thursday, October 13. com uses cookies on this site. Theratechnologies Inc. Theratechnologies Unveils New Positive Data for Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers Stockhouse. Presented in part at the XVI International AIDS Conference; August 13–18, 2006; Toronto, Canada (abstracts TUP30058 AND THLB0218). Theratechnologies . 9 million as at August 31, 2023. TO) stock quote, history, news and other vital information to help you with your stock trading and investing. TH | September 26, 2023. (TSX: TH, Forum) noted that its Q1 2022 consolidated sales grew 20%, supported by 35% growth in sales of EGRIFTA SV formulation. 04) earnings per share (EPS) for the quarter. home message. 68 to a day high of $1. 's motion for leave to commence. com. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business. communications@theratech. 124. THTX earnings call for the period ending February 29, 2020. By continuing to use our service, you agree to our use of cookies. , that crews have been mobilized to prepare for the 2022 exploration program at the Treaty Creek property, located in the heart of the. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it plans to pursue Phase 3 clinical development of tesamorelin for the treatment of Non-Alcoholic Steatohepatitis (NASH) in. It’s lead investigational peptide drug conjugate linked to docetaxel, a well-established and well-characterized cytotoxic agent used in the. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 75. (2019-08-12 | TSX:TH) Theratechnologies Files Application to List on NASDAQ. com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. By exploiting the SORT1 function in ligand internalization, a new anticancer treatment strategy was designed to target SORT1‐positive TNBC‐derived cells both in vitro and in two in vivo tumor xenografts. Join the discussion: Find out what everybody’s saying about this stock on the Theratechnologies Bullboard, and check out the rest of Stockhouse’s stock forums and message boards. . TH | September 5, 2023. Get the latest Theratechnologies Inc (THTX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi. (THTX) Stock Price, Quote & News - Stock Analysis -20. Montréal, Québec, Canada . ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has established an at-the-market ("ATM") equity program allowing Theratechnologies to issue and sell up to US $50 million common shares from. The business had revenue of $27. By continuing to use our service, you agree to our use of cookies. 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Amount of cash a business has after it has met its financial obligations such as debt and outstanding payments. 89 52. Stable Share Price: TH is more volatile than 90% of Canadian stocks over the past 3 months, typically moving +/- 25% a week. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. NCU. Gain a better understanding of ETFs with our ETF Insights and ETF 101 resource. T. (2022-02-10 | TSX:TH) Theratechnologies to Announce Financial Results for Its Fourth Quarter and Full Fiscal Year 2021. MONTREAL, Sept. (NASDAQ:NASDAQ:THTX) Q1 2022 Earnings Conference Call April 13, 2022 8:30 AM ETCompany ParticipantsPaul Levesque - President & CEOPhilippe Dubuc - SVP &. Trogarzo ® is a long-acting, CD4-directed, post-attachment HIV-1 inhibitor. The website address for Stockhouse has changed We changed the address of the Stockhouse website from to stockhouse. Cookies are used to offer you a better browsing experience and to analyze our traffic. is a speaker and consultant of Theratechnologies. com uses cookies on this site.